Company & Sponsor Intelligence

UCB Biopharma S.P.R.L.

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials4

Recruiting0

Completed2

Countries1

Therapeutic footprint

epilepsyparkinsons

Indexed studies

NCT02161185A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
epilepsy · United StatesPHASE3

NCT03405714A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy
epilepsy · United StatesPHASE2

NCT01390220Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters
epilepsy · United StatesPHASE3

NCT03103919Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management
parkinsons · United StatesPHASE4

Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →